Long-term eradication of extranodal natural killer/T-cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells

Animals Epstein-Barr Virus Infections / therapy Herpesvirus 4, Human Induced Pluripotent Stem Cells Killer Cells, Natural Lymphoma, Extranodal NK-T-Cell / therapy Lymphoma, T-Cell Mice

Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
03 2020
Historique:
received: 02 04 2019
accepted: 10 07 2019
pubmed: 13 7 2019
medline: 28 4 2021
entrez: 13 7 2019
Statut: ppublish

Résumé

Functionally rejuvenated induced pluripotent stem cell (iPSC)-derived antigen-specific cytotoxic T lymphocytes (CTL) are expected to be a potent immunotherapy for tumors. When L-asparaginase-containing standard chemotherapy fails in extranodal natural killer/T-cell lymphoma, nasal type (ENKL), no effective salvage therapy exists. The clinical course then is miserable. We demonstrate prolonged and robust eradication of ENKL

Identifiants

DOI: 10.3324/haematol.2019.223511 PMID: 31296577 PMC: PMC7049350
pubmed: 31296577
pii: haematol.2019.223511
doi: 10.3324/haematol.2019.223511
pmc: PMC7049350
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

796-807

Informations de copyright

Copyright© 2020 Ferrata Storti Foundation.

Références

Clin Cancer Res. 2012 Mar 15;18(6):1611-8
pubmed: 22271878
Stem Cell Reports. 2015 Oct 13;5(4):597-608
pubmed: 26321144
Blood. 2001 Feb 15;97(4):835-43
pubmed: 11159505
Blood. 2007 Oct 15;110(8):2838-45
pubmed: 17609424
Blood. 2013 Jun 20;121(25):4997-5005
pubmed: 23652805
Mol Ther. 2017 Sep 6;25(9):2214-2224
pubmed: 28602436
Blood. 2003 Mar 1;101(5):1905-12
pubmed: 12411306
Nat Immunol. 2013 Dec;14(12):1212-8
pubmed: 24240160
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Blood. 2010 Feb 4;115(5):925-35
pubmed: 19880495
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Science. 2002 Oct 25;298(5594):850-4
pubmed: 12242449
J Clin Oncol. 2005 Apr 1;23(10):2346-57
pubmed: 15800326
N Engl J Med. 1988 Dec 22;319(25):1676-80
pubmed: 3264384
Ann Oncol. 2016 Jul;27(7):1362
pubmed: 27072927
Blood. 1998 Sep 1;92(5):1549-55
pubmed: 9716582
Br J Haematol. 2005 Sep;130(6):860-8
pubmed: 16156856
Nat Rev Immunol. 2012 Mar 22;12(4):269-81
pubmed: 22437939
Nat Rev Clin Oncol. 2012 Sep;9(9):510-9
pubmed: 22801669
Exp Hematol. 2017 Mar;47:2-12
pubmed: 27826124
Blood. 1999 Jan 15;93(2):599-606
pubmed: 9885221
Blood. 2015 Nov 5;126(19):2193-201
pubmed: 26239088
Cell Stem Cell. 2013 Jan 3;12(1):114-26
pubmed: 23290140
Br J Haematol. 2007 Nov;139(4):532-44
pubmed: 17916099
J Clin Oncol. 2011 Nov 20;29(33):4410-6
pubmed: 21990393
Blood. 2017 Apr 27;129(17):2437-2442
pubmed: 28188133
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13866-71
pubmed: 11698646
Blood. 2008 Mar 15;111(6):3220-4
pubmed: 18203952
Blood. 2012 Oct 11;120(15):2973-80
pubmed: 22919026
J Clin Oncol. 2014 Mar 10;32(8):798-808
pubmed: 24344220
Blood. 2001 Feb 1;97(3):708-13
pubmed: 11157488
Nat Biotechnol. 2013 Oct;31(10):928-33
pubmed: 23934177

Auteurs

Miki Ando (M)

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan m-ando@juntendo.ac.jp.
Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Jun Ando (J)

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.

Satoshi Yamazaki (S)

Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Midori Ishii (M)

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.

Yumi Sakiyama (Y)

Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Sakiko Harada (S)

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.

Tadahiro Honda (T)

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.

Tomoyuki Yamaguchi (T)

Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Masanori Nojima (M)

Center for Translational Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Koichi Ohshima (K)

Department of Pathology, School of Medicine, Kurume University, Fukuoka, Japan.

Hiromitsu Nakauchi (H)

Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan nakauchi@stanford.edu.
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.

Norio Komatsu (N)

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Long-term eradication of extranodal natural...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus oncogènes › Infections à virus Epstein-Barr › Long-term eradication of extranodal natural...
questionsmedicales.fr › Virus › Virus oncogènes › Virus tumoraux à ADN › Gammaherpesvirinae › Lymphocryptovirus › Herpèsvirus humain de type 4 › Long-term eradication of extranodal natural...
questionsmedicales.fr › Cellules › Cellules souches › Cellules souches pluripotentes › Cellules souches pluripotentes induites › Long-term eradication of extranodal natural...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Cellules tueuses naturelles › Long-term eradication of extranodal natural...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Lymphome T-NK extraganglionnaire › Long-term eradication of extranodal natural...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome T › Long-term eradication of extranodal natural...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Long-term eradication of extranodal natural...